SCHEMBL530163

SCHEMBL530163

CCOC(=O)NS(N)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.46
FNTB P49356 1/20 0.46
PGGT1B P53609 1/20 0.46
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
GAA P10253 3/20 0.42
ALOX15 P16050 1/20 0.42
MGAM O43451 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
SOAT1 P35610 1/20 0.37
STS P08842 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138578 0.81 GAA (0.46) GAAALOX15MGAMSIMGAM2
SCHEMBL3412967 0.79 EPHX1 (0.48) CA1CA2ALDH1A1SMN1; SMN2STS
SCHEMBL3836989 0.79 GAA (0.44) GAAALOX15MGAMSIMGAM2
SCHEMBL9574919 0.79 GAA (0.44) GAAALOX15MGAMSIMGAM2
SCHEMBL5639931 0.79 GAA (0.46) GAAALOX15MGAMSIMGAM2
SCHEMBL23928061 0.77 GAA (0.42) GAAALOX15MGAMSIMGAM2
SCHEMBL530162 0.77 GAA (0.42) GAAALOX15MGAMSIMGAM2
SCHEMBL529835 0.77 GAA (0.42) GAAALOX15MGAMSIMGAM2
SCHEMBL25961960 0.77 GAA (0.42) GAAALOX15MGAMSIMGAM2
SCHEMBL7615141 0.77 EPHX1 (0.59) CA1CA2CA9STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2598556-B1 PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS WACKER CHEMIE AG (DE) 2014-09-03 EP claimed
US-8741979-B2 Process for producing siloxane copolymers with urethane-sulphonamido linking groups WACKER CHEMIE AG (DE) 2014-06-03 US claimed
US-20130123376-A1 PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS WACKER CHEMIE AG (DE) 2013-05-16 US claimed
CN-103025799-B Process for producing siloxane copolymers with urethane-sulphonamido linking groups WACKER CHEMIE AG 2015-03-11 CN disclosed
CN-103025799-B Process for producing siloxane copolymers with urethane-sulphonamido linking groups WACKER CHEMIE AG 2015-03-11 CN disclosed
US-8741979-B2 Process for producing siloxane copolymers with urethane-sulphonamido linking groups WACKER CHEMIE AG (DE) 2014-06-03 US disclosed
US-8741979-B2 Process for producing siloxane copolymers with urethane-sulphonamido linking groups WACKER CHEMIE AG (DE) 2014-06-03 US disclosed
US-8741979-B2 Process for producing siloxane copolymers with urethane-sulphonamido linking groups WACKER CHEMIE AG (DE) 2014-06-03 US disclosed
JP-2013536276-A 2013-09-19 JP disclosed
EP-2598556-A1 PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS Wacker Chemie AG (DE) 2013-06-05 EP disclosed
US-20130123376-A1 PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS WACKER CHEMIE AG (DE) 2013-05-16 US disclosed
US-20130123376-A1 PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS WACKER CHEMIE AG (DE) 2013-05-16 US disclosed
CN-103025799-A Process for producing siloxane copolymers with urethane-sulphonamido linking groups WACKER CHEMIE AG 2013-04-03 CN disclosed
CN-103025799-A Process for producing siloxane copolymers with urethane-sulphonamido linking groups WACKER CHEMIE AG 2013-04-03 CN disclosed
WO-2012013558-A1 PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS WACKER CHEMIE AG (DE) 2012-02-02 WO disclosed
EP-1230210-A1 AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-14 EP disclosed
WO-2001036375-A1 AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123376-A1 PROCESS FOR PRODUCING SILOXANE COPOLYMERS WITH URETHANE-SULPHONAMIDO LINKING GROUPS STS, MPST, IDUA FNTA 2980/4885FNTB 2359/4885PGGT1B 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.